Parkinson's drug may impact gum disease risk

NCT ID NCT07405268

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the Parkinson's drug Levodopa-Benserazide affects gum health and inflammation. Researchers will measure gum health and saliva markers in 136 people, including Parkinson's patients with and without gum disease, and healthy controls. The goal is to understand how this common medication might influence oral health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Levodopa-Benserazide

What this could lead to

If successful, this could help doctors understand how Parkinson's medication affects gum health, potentially leading to better dental care for patients.

What could go wrong

This is a small, observational study that only measures markers, not a treatment trial. Results may not apply to all Parkinson's patients or lead to direct changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIODONTAL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation Parkinson disease periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi

    Ankara, 06010, Turkey (Türkiye)